What Happened?
Monmouth Junction, NJ-based CytoSorbents Promoted Kathleen Bloch as Interim Chief Financial Officer
About the Company
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its flagship product, CytoSorb®, is approved in the European Union, distributed in 75 countries worldwide, and has accumulated more than 212,000 human treatments to date, to reduce "cytokine storm" and other toxins that can cause organ failure. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as CytoSorb, has received two U.S. FDA Breakthrough Device Designations to remove two separate blood thinners during cardiothoracic surgery, including ticagrelor and the direct oral anticoagulants (DOAC) apixaban and rivaroxaban, and is undergoing pivotal clinical studies.
About the Person
Kathleen Bloch is Interim Chief Financial Officer at CytoSorbents. Previously, Kathleen held various senior HR leadership roles in the industry.
Info Source
News
Short Profile